Evidence map›Paper›PMID 42252657›Full record

ArticleBiotechnology and bioengineering2026

Fouling-Free Inertial Microfluidic Cell Clarification for Lentivirus Manufacturing.

Dohyun Park, Alexander Bevacqua, Mingyang Cui, Marina Nichols, Jianzhu Chen, Jongyoon Han

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dohyun ParkResearch Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Alexander BevacquaResearch Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0002-1309-075X
Mingyang CuiResearch Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Marina NicholsDepartment of Physics, Boston College, Chestnut Hill, Massachusetts.
Jianzhu ChenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Jongyoon HanResearch Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-7215-1439

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
FDA HHS 1R01FD007480-03FDA HHS R01 FD007480National Science Foundation Graduate Research Fellowship Program 2141064NCI NIH HHS P30 CA014051Northpond Ventures
6 · The paper itself

Abstract

Lentiviral vectors (LVVs) are widely used as gene-delivery vehicles in cell and gene therapy, enabling stable integration of transgenes into target cells. However, efficient clarification of LVV harvest remains a major bottleneck in large-scale manufacturing, as conventional depth filtration often results in significant product loss. Here, we introduce a fouling-free microfluidic cell clarification (MCC) system that enables high-efficiency LVV recovery. By precisely controlling the harvest flow rate and adjusting the recirculated cell density by adding buffer, we established a quantitative relationship between clarification efficiency and throughput. Under optimized conditions, the MCC achieved > 95% product recovery while maintaining > 95% cell removal efficiency. The MCC process closely followed the theoretical recovery model assuming negligible product loss within the device. Across three independent batch operations, apparent average LVV recovery remained substantially higher than that of a benchmark process employing a cellulose depth filter-based process. Scalability tests demonstrated consistent performance at flow rates up to 1.5 L/h without loss of clarification efficiency, demonstrating its potential for large-scale biomanufacturing. Beyond LVVs, the MCC platform is broadly applicable to cell-based modalities that secrete therapeutic products, offering a continuous, low-shear, and fouling-free alternative to conventional filtration processes.

Indexed as

Genetic VectorsLentivirusMicrofluidic Analytical TechniquesHumans

Identifiers

PMID42252657
PMCPMC13521457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.